Estrogen receptor mutations in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Estrogen receptor (ER) presence indicates better prognosis and survival in breast cancer patients.
• ER status guides hormonal intervention, yet only half of ER-positive patients respond to treatment.
• Hormonal therapy resistance develops even when ER is present, suggesting a need for functional assessment beyond simple presence.

Purpose of the Study:

• To investigate the role of estrogen receptor (ER) sequence variants in breast cancer progression and treatment resistance.
• To propose that identified ER mutations contribute to receptor dysfunction in vivo.
• To review ER mutations potentially implicated in the development of hormonally unresponsive breast cancer.

Main Methods:

• Review of existing literature on ER sequence variants in breast cancer cell lines and tumor specimens.
• Analysis of hypotheses regarding mutated or truncated steroid receptors causing hormone independence.
• Correlation of identified ER mutations with observed clinical outcomes and treatment responses.

Main Results:

• Estrogen receptor (ER) presence is a key prognostic marker in breast cancer.
• A significant proportion of ER-positive breast cancers become resistant to hormonal therapies.
• Loss of ER expression in tumors over time is infrequent, suggesting other mechanisms for resistance.

Conclusions:

• Simple ER presence measurement is insufficient to predict treatment response.
• Mutated or truncated ER variants may lead to constitutive receptor activity and hormone independence.
• Further research into specific ER mutations is crucial for understanding and overcoming breast cancer treatment resistance.